Vimarsana
Biggest News Aggregation in the World

Page 3 - Tissue Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tissue Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tissue Technologies Today - Breaking & Trending Today

INTEGRA LIFESCIENCES HOLDING CORPORATION (NASDAQ:IART) SHAREHOLDER ... - Vimarsana News

INTEGRA LIFESCIENCES HOLDING CORPORATION (NASDAQ:IART) SHAREHOLDER ...

INTEGRA LIFESCIENCES HOLDING CORPORATION (NASDAQ:IART) SHAREHOLDER ...

INTEGRA LIFESCIENCES HOLDING CORPORATION SHAREHOLDER ALERT: Bernstein ... - Vimarsana News

INTEGRA LIFESCIENCES HOLDING CORPORATION SHAREHOLDER ALERT: Bernstein ...

INTEGRA LIFESCIENCES HOLDING CORPORATION SHAREHOLDER ALERT: Bernstein ...

Gainey McKenna & Egleston Announces A Class Action Lawsuit - Vimarsana News

Gainey McKenna & Egleston Announces A Class Action Lawsuit

NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United...

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Clas - Vimarsana News

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Clas

NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit in the U.S. District Court for the District of New Jersey alleging violations of federal securities laws by Integra LifeSciences Holdings Corporation (“Integra” or the...

Integra LifeSciences (NASDAQ:IART) Cut to "Underweight" at Morgan Stanley - Vimarsana News

Integra LifeSciences (NASDAQ:IART) Cut to "Underweight" at Morgan Stanley

Morgan Stanley lowered shares of Integra LifeSciences (NASDAQ:IART – Free Report) from an equal weight rating to an underweight rating in a research report released on Thursday, MarketBeat Ratings reports. Morgan Stanley currently has $44.00 price target on the life sciences company’s stock. A number of other equities analysts also recently weighed in on the […]

Source: wkrb13.com